GlassScriptPhysician profile
Matthew A Lange
NPI 1063775716
$24,816.94
in general payments reported to CMS, 2019-2025
33 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,121 · 2020: $356 · 2021: $14K · 2022: $1,656 · 2023: $4,102 · 2024: $878 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,514 · Travel and Lodging: $2,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,514.46 |
| Travel and Lodging | $2,480.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,937.23 | 2019-2023 | Da Vinci Surgical System |
| W. L. Gore & Associates, INC. | $2,589.10 | 2019-2025 | Seamguard, Gore Bio-A Tissue Reinforcement, Gore Enform Preperitoneal Biomaterial |
| Medical Device Business Services, INC. | $1,883.74 | 2019-2023 | Echelon; Endopath |
| Ethicon US, LLC | $1,624.69 | 2019-2025 | Echelon Flex, Enseal, Echelon Endopath |
| Apollo Endosurgery US INC | $1,321.47 | 2019-2020 | |
| Medtronic, INC. | $997.64 | 2023-2025 | Signia, Appose Ulc, Signet |
| Novo Nordisk INC | $607.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Davol INC. | $323.71 | 2019-2024 | Phasix Mesh |
| Boston Scientific Corporation | $311.51 | 2025 | Overstitch Endoscopic Suturing System |
| Kerecis Limited | $117.46 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Rhythm Pharmaceuticals, INC. | $107.70 | 2023 | Imcivree |
| Dilon Technologies, INC. | $106.73 | 2025 | Hemoblast Bellows |
| Endo Pharmaceuticals INC. | $99.37 | 2019-2022 | |
| Abbott Laboratories | $90.98 | 2019 | |
| Lilly USA, LLC | $87.44 | 2024-2025 | Zepbound, Mounjaro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $85.96 | 2019-2022 | |
| Hollister Incorporated | $69.71 | 2022 | |
| Abbvie INC. | $63.34 | 2025 | |
| Trevena, INC. | $61.32 | 2022 | |
| Tela Bio, INC. | $55.99 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.52 | 2021 | |
| Kvk-Tech, INC. | $30.35 | 2024 | |
| Covidien LP | $29.48 | 2019-2020 | |
| Shire North American Group INC | $27.57 | 2019 | |
| Allergan, INC. | $23.17 | 2019 | |
| Thd America, INC. | $20.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.93 | 2019 | |
| Teleflex LLC | $18.00 | 2020 | |
| Axonics, INC. | $16.42 | 2023 | Axonics |
| Kci USA, INC. | $15.71 | 2022 | |
| Corcept Therapeutics | $15.44 | 2025 | Korlym |
| Tactile Systems Technology INC | $14.05 | 2024 | Flexitouch Plus, Entre Plus |
| Redhill Biopharma INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.